Digital
DATA MARKET SERVICES
Data Market Services aims to overcome the barriers in the way of SMEs and data-driven start-ups to market success.
therapies
Decision on combinatorial therapies in immune-mediated diseases using systemic approaches
Project dates
2020-2025
Website
Role of Zabala
PARTNER
Project led by
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
10
Partners
6
Countries
6.2
M€ Budget
5
Years
Immune-mediated Inflammatory Diseases (IMIDs) are a group of diseases caused by inappropriate activation of the immune system in cells and organs. They are relatively common and affect up to 7% of the general population, being the third most common type of disease in developed countries. In the DoCTIS project, we focus on six of the most frequent IMIDs in our society: rheumatoid arthritis (RA), psoriasis (PsA), psoriatic arthritis (PsA), Crohn’s disease (CD), ulcerative colitis (UC) and systemic lupus erythematosus (SLE). In these six diseases, chronic activation of the powerful immune system ultimately affects the functionality of many tissues and organs, such as the joints in RA and PsA or the gut in CD and UC. This clearly reduces the quality of life of many patients, as well as increases the risk of other diseases and shortens life expectancy.
The last 20 years have seen a breakthrough in the development of therapies to treat IMIDs. These therapies have been an improvement over previous drugs, helping reduce the impact on a significant percentage of patients. However, many other patients do not respond adequately to these new therapies. Moreover, in many cases, these new therapies eventually lose efficacy and must be discontinued. These therapies are expensive and have become a major burden on European healthcare systems.
The DoCTIS project is designed to address this major health problem in IMIDs. To do this, we will identify new combinations of existing drugs that enhance the effect of each other. This combinatorial effect will have many beneficial aspects for IMID patients: it will reduce disease activity to remission (i.e. no symptoms), it will reduce the dose of the drugs (and thus the risk of toxicity) and, finally, it will reduce the likelihood of becoming resistant to therapy.
The DoCTIS project will integrate different experts from clinical, biological, computational and epidemiological fields. These experts will collaborate to generate and analyse high-throughput data generated from IMID patients, as well as animal models of the disease, to identify new drug combinations that are highly effective.
“Within the realm of IMIDs, the DoCTIS project emerges as a beacon of hope. Through the strategic identification of synergistic drug combinations, we aim to revolutionize treatment approaches”
Laura Sesma
Team leader expert in European Programmes in the Health Area
Digital
Data Market Services aims to overcome the barriers in the way of SMEs and data-driven start-ups to market success.
Industry
The main objective of MAGICIAN will be to develop robotic solutions which will identify and repair defects in manufacturing products...
Security and defence
S4AllCities integrates advanced technological and organizational solutions in a market oriented unified Cyber – Physical Security Management framework, aiming at...
News
The EU- funded project “Digital Innovation Hubs Federation For Large Scale adoption of digital technologies by European SMEs” announces has announced the results of its first call for applications: 14 applicants of the 72 eligible proposals will receive a total of over 1.1 million euros to develop their smart applications.
Opinion
EXTERNAL FINANCING INSTRUMENTS
Paola Votta
Third Countries Knowledge Area Leader
Publication
CITIES
Find out about European funding opportunities to help build sustainable cities
The important thing is not to keep moving, but rather to know in which direction to go. Our 37% success rate proves that we know how to guide our clients.
Our compass is our clients; our mission is to solve their problems, guiding them so that innovation becomes their key to competitiveness.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!
This website uses the following additional cookies:
(List the cookies that you are using on the website here.)
Please enable Strictly Necessary Cookies first so that we can save your preferences!